BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 18339194)

  • 1. Gaucher disease: improving management.
    Bembi B; Deegan P
    Acta Paediatr; 2008 Apr; 97(457):81-2. PubMed ID: 18339194
    [No Abstract]   [Full Text] [Related]  

  • 2. Treatment of Gaucher's disease with OGT 918.
    Mistry PK
    Lancet; 2000 Aug; 356(9230):676-7. PubMed ID: 10968454
    [No Abstract]   [Full Text] [Related]  

  • 3. Gaucher disease: unmet treatment needs.
    Mehta A
    Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treating patients with Gaucher disease and parkinsonism: misrepresentation in a title.
    Goker-Alpan O; Sidransky E
    Parkinsonism Relat Disord; 2008; 14(1):81-2; author reply 83. PubMed ID: 17350320
    [No Abstract]   [Full Text] [Related]  

  • 5. Imino sugar therapy for type 1 Gaucher disease.
    Priestman DA; Platt FM; Dwek RA; Butters TD
    Glycobiology; 2000 Nov; 10(11):iv-vi. PubMed ID: 11221677
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment of Gaucher's disease with OGT 918.
    Kranda M
    Lancet; 2000 Aug; 356(9230):677. PubMed ID: 10968455
    [No Abstract]   [Full Text] [Related]  

  • 7. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
    Hachulla E; Javier RM
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S180-2. PubMed ID: 18228685
    [No Abstract]   [Full Text] [Related]  

  • 8. Substrate reduction therapy.
    Platt FM; Jeyakumar M
    Acta Paediatr; 2008 Apr; 97(457):88-93. PubMed ID: 18339196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
    Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
    [No Abstract]   [Full Text] [Related]  

  • 10. [Organization of Gaucher disease management in France].
    Stirnemann J; de Villemeur TB; Belmatoug N
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S198-201. PubMed ID: 18228688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Osteoarticular manifestations of Gaucher disease in adults: pathophysiology and treatment].
    Javier RM; Hachulla E
    Presse Med; 2007 Dec; 36(12 Pt 3):1971-84. PubMed ID: 17498916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gaucher disease: hematologic and oncologic implications.
    Hughes D
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
    [No Abstract]   [Full Text] [Related]  

  • 13. [Therapeutic objectives in Gaucher disease].
    Mistry P; Germain DP
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S171-5. PubMed ID: 18228683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current development and usefulness of biomarkers for Gaucher disease follow up].
    Maire I; Guffon N; Froissart R
    Rev Med Interne; 2007 Oct; 28 Suppl 2():S187-92. PubMed ID: 18228687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New data on Gaucher's disease].
    Stirnemann J
    Rev Med Interne; 2008 Mar; 29(3):176-8. PubMed ID: 17964006
    [No Abstract]   [Full Text] [Related]  

  • 16. Therapeutic goals in Gaucher disease.
    Mistry P; Germain DP
    Rev Med Interne; 2006 Mar; 27 Suppl 1():S30-8. PubMed ID: 16644400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.
    Giraldo P; Alfonso P; Atutxa K; Fernández-Galán MA; Barez A; Franco R; Alonso D; Martin A; Latre P; Pocovi M
    Haematologica; 2009 Dec; 94(12):1771-5. PubMed ID: 19608672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gaucher disease due to saposin C deficiency, previously described as non-neuronopathic form--no positive effects after 2-years of miglustat therapy.
    Tylki-Szymańska A; Groener JE; Kamiński ML; Ługowska A; Jurkiewicz E; Czartoryska B
    Mol Genet Metab; 2011 Dec; 104(4):627-30. PubMed ID: 21978771
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the Next Barriers to Successful Therapy.
    Cohen IJ; Baris H; Mistry PK; Sands MS
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():629. PubMed ID: 27491209
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of miglustat as maintenance therapy after enzyme therapy in adults with stable type 1 Gaucher disease: a prospective, open-label non-inferiority study.
    Cox TM; Amato D; Hollak CE; Luzy C; Silkey M; Giorgino R; Steiner RD;
    Orphanet J Rare Dis; 2012 Dec; 7():102. PubMed ID: 23270487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.